Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer

PURPOSE: Patients with KRAS-mutant non–small cell lung cancer (NSCLC) with brain metastases (BM) have a poor prognosis. Adagrasib (MRTX849), a potent oral small-molecule KRAS(G12C) inhibitor, irreversibly and selectively binds KRAS(G12C), locking it in its inactive state. Adagrasib has been optimize...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabari, Joshua K., Velcheti, Vamsidhar, Shimizu, Kazuhide, Strickland, Matthew R., Heist, Rebecca S., Singh, Mohini, Nayyar, Naema, Giobbie-Hurder, Anita, Digumarthy, Subba R., Gainor, Justin F., Rajan, Anant P., Nieblas-Bedolla, Edwin, Burns, Aaron C., Hallin, Jill, Olson, Peter, Christensen, James G., Kurz, Sylvia C., Brastianos, Priscilla K., Wakimoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662862/
https://www.ncbi.nlm.nih.gov/pubmed/35404402
http://dx.doi.org/10.1158/1078-0432.CCR-22-0383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662862/
https://www.ncbi.nlm.nih.gov/pubmed/35404402
http://dx.doi.org/10.1158/1078-0432.CCR-22-0383

Ejemplares similares